Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.

Kersten MJ, Dreyling M, Linton KM, Chitu D, Zwezerijnen GJC, Tonino SH, Kap M, Liu R, Van Hooije C, Chamuleau MED, Visser HPJ, De Jongh E, Marijt EAF, Leys MBL, Bilgin YM, Dürig J, McKay P, Snijders T, Pettitt A, Minnema MC, Prange-Krex G, Cuijpers MLH, Bohmer LH, Tick LW, Florschutz A, Silbermann M, Fijnheer R, Beeker A, Tolboom N, Mitea C, Arens AIJ, Wiegers SE, Heymans MW, Klapper W, Coupland SE, De Jong D, Doorduijn JK, Zijlstra JM

Open source

DOI: 10.3324/haematol.2025.300152
Published: 2026 Apr 16
Container: Haematologica
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2025.300152,
  title = {Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.},
  author = {Kersten MJ and Dreyling M and Linton KM and Chitu D and Zwezerijnen GJC and Tonino SH and Kap M and Liu R and Van Hooije C and Chamuleau MED and Visser HPJ and De Jongh E and Marijt EAF and Leys MBL and Bilgin YM and Dürig J and McKay P and Snijders T and Pettitt A and Minnema MC and Prange-Krex G and Cuijpers MLH and Bohmer LH and Tick LW and Florschutz A and Silbermann M and Fijnheer R and Beeker A and Tolboom N and Mitea C and Arens AIJ and Wiegers SE and Heymans MW and Klapper W and Coupland SE and De Jong D and Doorduijn JK and Zijlstra JM},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2025.300152},
  url = {https://doi.org/10.3324/haematol.2025.300152}
}

RIS

TY  - JOUR
TI  - Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.
AU  - Kersten MJ
AU  - Dreyling M
AU  - Linton KM
AU  - Chitu D
AU  - Zwezerijnen GJC
AU  - Tonino SH
AU  - Kap M
AU  - Liu R
AU  - Van Hooije C
AU  - Chamuleau MED
AU  - Visser HPJ
AU  - De Jongh E
AU  - Marijt EAF
AU  - Leys MBL
AU  - Bilgin YM
AU  - Dürig J
AU  - McKay P
AU  - Snijders T
AU  - Pettitt A
AU  - Minnema MC
AU  - Prange-Krex G
AU  - Cuijpers MLH
AU  - Bohmer LH
AU  - Tick LW
AU  - Florschutz A
AU  - Silbermann M
AU  - Fijnheer R
AU  - Beeker A
AU  - Tolboom N
AU  - Mitea C
AU  - Arens AIJ
AU  - Wiegers SE
AU  - Heymans MW
AU  - Klapper W
AU  - Coupland SE
AU  - De Jong D
AU  - Doorduijn JK
AU  - Zijlstra JM
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2025.300152
UR  - https://doi.org/10.3324/haematol.2025.300152
ER  -

APA

MJ, K., M, D., KM, L., D, C., GJC, Z., SH, T., M, K., R, L., C, V. H., MED, C., HPJ, V., E, D. J., EAF, M., MBL, L., YM, B., J, D., P, M., T, S., A, P., MC, M., G, P., MLH, C., LH, B., LW, T., A, F., M, S., R, F., A, B., N, T., C, M., AIJ, A., SE, W., MW, H., W, K., SE, C., D, D. J., JK, D., & JM, Z. (2026). Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.. Haematologica. https://doi.org/10.3324/haematol.2025.300152

Source records

pubmed · retrieved 2026-09-26T05:01:54.523Z